Posttransplant cyclophosphamide versus anti‐thymocyte globulin versus combination for graft‐versus‐host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party
Abdul Hamid Bazarbachi(NewYork–Presbyterian Hospital), Mohamad Mohty(Sorbonne Université)
Cited by 18
Related Papers
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
|Nature Medicine|2023|534
One million haemopoietic stem-cell transplants: a retrospective observational study
|The Lancet Haematology|2015|434